Kizilgul Muhammed, Beysel Selvihan, Ozcelik Ozgur, Kan Seyfullah, Apaydin Mahmut, Caliskan Mustafa, Ucan Bekir, Sencar Erkam, Ozdemir Seyda, Cakal Erman
Endocr Pract. 2017 Jun;23(6):662-668. doi: 10.4158/EP161713.OR. Epub 2017 Mar 23.
Pentraxin 3 (PTX3) is an acute-phase glycoprotein, which is increased in patients with cardiovascular disease (CVD) and considered as a predictor of CVD in the general population. Both functional and nonfunctional adrenal tumors are associated with a higher risk of cardiovascular events and mortality. We aimed to investigate plasma PTX3 levels in patients with functioning and nonfunctioning adrenal tumors and determine its relationship with cardiovascular risk factors.
Twenty-one patients with functional adrenal tumors (11 pheochromocytomas, 9 Cushing syndrome, and 1 primary hyperaldosteronism), 28 patients with nonfunctional adrenal incidentalomas, and 40 healthy controls were enrolled in the study. Serum PTX3 levels were measured using a human PTX3 enzyme-linked immunosorbent assay.
PTX3 concentrations were significantly higher in the adrenal tumor group compared with the control group (3,001.64 ± 374.64 pg/mL vs. 1,173.59 ± 168.89 pg/mL; P<.001). PTX3 concentrations were positively correlated with carotid intima media thickness (CIMT) (r, 0.464; P<.001), high-sensitivity C-reactive protein (hsCRP) (r, 0.551; P<.001), diastolic blood pressure (r, 0.334; P = .003), systolic blood pressure (r, 0.312; P = .006), and urinary metanephrine concentrations (r, 0.320; P = .041). Serum PTX3 concentrations in patients with functional adrenal tumors and comorbidities including hypertension, diabetes mellitus, or CVD were higher than in those without comorbidities (3,654.54 ± 447 pg/mL vs. 1,026.96 ± 447.97 pg/mL; P = .008).
We found that serum PTX3 concentrations increased in both functional and nonfunctional adrenal tumors. PTX3 levels were correlated with cardiovascular risk factors such as CIMT, hsCRP, and blood pressure.
BMI = body mass index; CIMT = carotid intima-media thickness; CRP = C-reactive protein; CT = computed tomography; CVD = cardiovascular disease; FGF2 = fibroblast growth factor 2; hsCRP = high-sensitivity C-reactive protein; PA = primary hyperaldosteronism; PTX3 = pentraxin 3.
五聚体3（PTX3）是一种急性期糖蛋白，在心血管疾病（CVD）患者中水平升高，被认为是一般人群中CVD的预测指标。功能性和非功能性肾上腺肿瘤均与心血管事件和死亡风险较高相关。我们旨在研究功能性和非功能性肾上腺肿瘤患者的血浆PTX3水平，并确定其与心血管危险因素的关系。
本研究纳入了21例功能性肾上腺肿瘤患者（11例嗜铬细胞瘤、9例库欣综合征和1例原发性醛固酮增多症）、28例非功能性肾上腺偶发瘤患者和40例健康对照者。采用人PTX3酶联免疫吸附测定法检测血清PTX3水平。
肾上腺肿瘤组的PTX3浓度显著高于对照组（3001.64±374.64 pg/mL对1173.59±168.89 pg/mL；P<0.001）。PTX3浓度与颈动脉内膜中层厚度（CIMT）（r=0.464；P<0.001）、高敏C反应蛋白（hsCRP）（r=0.551；P<0.001）、舒张压（r=0.334；P=0.003）、收缩压（r=0.312；P=0.006）及尿间甲肾上腺素浓度（r=0.320；P=0.041）呈正相关。合并高血压、糖尿病或CVD等疾病的功能性肾上腺肿瘤患者的血清PTX3浓度高于未合并疾病的患者（3654.54±447 pg/mL对1026.96±447.97 pg/mL；P=0.008）。
我们发现功能性和非功能性肾上腺肿瘤患者的血清PTX3浓度均升高。PTX3水平与CIMT、hsCRP和血压等心血管危险因素相关。
BMI=体重指数；CIMT=颈动脉内膜中层厚度；CRP=C反应蛋白；CT=计算机断层扫描；CVD=心血管疾病；FGF2=成纤维细胞生长因子2；hsCRP=高敏C反应蛋白；PA=原发性醛固酮增多症；PTX3=五聚体3
